Skip to main content
Fig. 6 | BMC Medicine

Fig. 6

From: Organ-specific metastatic landscape dissects PD-(L)1 blockade efficacy in advanced non-small cell lung cancer: applicability from clinical trials to real-world practice

Fig. 6

METscore enables classification of survival benefits from first-line checkpoint blockade-based immunotherapy. Kaplan-Meier curves of A overall survival and B progression-free survival according to METscore groups (≥ 3 vs. < 3) for patients receiving atezolizumab as first-line therapy within PD-L1-selected FIR and BIRCH trials. Kaplan-Meier curves of C overall survival and D progression-free survival according to METscore groups for patients receiving ICIs as first-line therapy within the PD-L1-selected NFyy cohort. Abbreviations: ICI, immune checkpoint inhibitor; HR, hazard ratio; CI, confidence interval; PD-L1, programmed death-ligand 1

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us